| 英文別名： |
Silodosin;Silodosin-d4;Silodoxin;1H-Indole-7-carboxaMide,2,3-dihydro-1-(3-hydroxypropyl)-5-[(2R)-2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]aMino]propyl]-;1-(3-hydroxypropyl)-5-[(2R)-({2-[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl}aMino)propyl]indoline-7-carboxaMide;(–)-1-(3-Hydroxypropyl)-5-[(2R)-2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]amino]propyl]-2,3-di-hydro-1H-indole-7-carboxamide;KAD 3213;KMD 3213;Silodosin, 98%, an α1-adrenoceptor antagonist;Silodosin(Rapaflo);Silodosin API;[
""
];1-(3-Hydroxypropyl)-5-[(2R)-2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]amino]propyl]-2,3-dihydro-1H-indole-7-carboxamide;Rapallo;1-(3-Hydroxypropyl)-5-[(2R)-2-({2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl}amino)propyl]-2,3-dihydro-1H-indole-7-carboxamide;Urief;UNII-CUZ39LUY82;Silodyx;Rapaflo;KMD-3213;1-(3-hydroxypropyl)-5-[(2R)-2-({2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl}amino)propyl]-2,3-dihydro-1H-indole-7-carboxamide;[3H]-Silodosin;[14C]-Silodosin;2,3-dihydro-1-(3-hydroxypropyl)-5-[(2R)-2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]amino]propyl]-1H-Indole-7-carboxamide;1-(3-hydroxypropyl)-5-[(2R)-2-[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethylamino]propyl]-2,3-dihydroindole-7-carboxamide;(R)-1-(3-hydroxypropyl)-5-(2-((2-(2-(2,2,2-trifluoroethoxy)phenoxy)ethyl)amino)propyl)indoline-7-carboxamide |
| 中文別名： |
西洛多辛;西洛多辛及中間體;西羅多辛-D4;西洛多辛(標(biāo)準(zhǔn)品);西洛多辛雜質(zhì);2,3-二氫-1-(3-羥丙基)-5-[(2R)-2-[2-[2-(2,2,2-三氟乙氧基)苯氧基]乙胺基]丙基]-1H-吲哚-7-甲酰胺;2,3-二氫-1-(3-羥基丙基)-5-[(2R)-2-[2-[2-(2,2,2-三氟乙氧基)苯氧基]乙胺基]丙基]-1H-吲哚-7-甲酰胺;西羅多辛;西洛多辛, 一種Α1-腎上腺素受體拮抗劑;西洛多辛(R);西洛多辛原料藥;西洛多辛A;西洛多辛異構(gòu)體;西洛多辛標(biāo)準(zhǔn)品;西洛多辛(R-異構(gòu)體);西洛多辛（R）;西洛多辛 西羅多辛;賽洛多辛 |
.png)
滬公網(wǎng)安備 31011502020044號(hào)
危險(xiǎn)化學(xué)品經(jīng)營許可證
水濤